Avalo Therapeutics, Inc. (AVTX)

13.21 +0.35 (+2.72%) USD  |  NASDAQ  |  Apr 29, 16:00
13.21 0.00 (0.00%) After-Hours: 16:15
More

Avalo Therapeutics Revenue Estimates for Current Fiscal Year

Revenue Estimates for Current Fiscal Year Chart

View Revenue Estimates for Current Fiscal Year for AVTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Current Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Current Fiscal Year Range, Past 5 Years

View Revenue Estimates for Current Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Current Fiscal Year Benchmarks

View Revenue Estimates for Current Fiscal Year Benchmarks
Start Trial
Catalyst Pharmaceuticals, Inc. Upgrade
AbbVie, Inc. Upgrade
Relmada Therapeutics, Inc. Upgrade
Theravance Biopharma, Inc. Upgrade
Corcept Therapeutics, Inc. Upgrade

Revenue Estimates for Current Fiscal Year Related Metrics

EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade